Dostarlimab-gxly

(Jemperli)

Dostarlimab-gxly

Drug updated on 11/15/2023

Dosage FormInjection (intravenous; 500 mg/10 mL (50 mg/mL))
Drug ClassProgrammed death receptor-1 (PD-1)–blocking antibodies
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated in combination with carboplatin and paclitaxel, followed by JEMPERLI as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microsatellite instability-high (MSI-H).
  • Indicated as a single agent for the treatment of adult patients with dMMR recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinumcontaining regimen in any setting and are not candidates for curative surgery or radiation.
  • Indicated as a single agent for the treatment of adult patients with dMMR recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.